Company Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:33:12 2024-05-01 pm EDT			5-day change	1st Jan Change
0.245 ^CAD	+2.08%		+2.08%	+28.95%

Apr. 29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

CAD in Million	2021	Weight	2022	Weight	Delta
Active Ingredient Product Technology 100.0 %	17	99.8 %	19	100.0 %	+9.82%

CAD in Million	2021	Weight	2022	Weight	Delta
United States 58.8 %	11	66.2 %	11	58.8 %	-2.79%
Germany 31.5 %	4	23.3 %	6	31.5 %	+48.30%
China 9.2 %	2	9.7 %	2	9.2 %	+3.20%
Other 0.4 %	0	0.4 %	0	0.4 %	+11.10%
Canada 0.2 %	0	0.4 %	0	0.2 %	-45.15%

Managers	Title	Age	Since
Gilles Gagnon CEO	Chief Executive Officer	70	06-12-31
Stacy Prefontaine DFI	Director of Finance/CFO	-	15-05-04
Mitch Regnier CTO	Chief Tech/Sci/R&D Officer	-	23-04-30
Paul Moquin CTO	Chief Tech/Sci/R&D Officer	-	18-01-31
Bernhard Seifried CTO	Chief Tech/Sci/R&D Officer	-	09-12-31
Jacqueline Eskander Ebrahim LAW	General Counsel	-	-
Leoni DeJoya PRN	Corporate Officer/Principal	-	19-01-06
Jenene Thomas		52	-

Members of the board	Title	Age	Since
Gilles Gagnon CEO	Chief Executive Officer	70	06-12-31
Ulrich Kosciessa BRD	Director/Board Member	-	15-04-26
William Li BRD	Director/Board Member	61	14-11-19
Ronald Miller CHM	Chairman	-	22-03-01
Geneviève Foster BRD	Director/Board Member	-	22-04-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	78,293,177	75,156,073 ( 95.99 %)	0	95.99 %

Name	Equities	%	Valuation
Gilles Gagnon 2.221 %	1,739,000	2.221 %	295 630 $
Glenn Rourke 1.465 %	1,146,636	1.465 %	194 928 $
Leoni DeJoya 0.1405 %	110,000	0.1405 %	18 700 $
William Li 0.1297 %	101,579	0.1297 %	17 268 $
Ulrich Kosciessa 0.1000 %	78,327	0.1000 %	13 316 $
Stacy Prefontaine 0.0415 %	32,500	0.0415 %	5 525 $
Ronald Miller 0.000000 %	0	0.000000 %	- $
Geneviève Foster 0.000000 %	0	0.000000 %	- $

Ceapro, Inc.

51 Avenue North West Suite 7824

T6E 6W2, Edmonton

http://www.ceapro.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CEAPRO INC.	+28.95%	13.94M
MODERNA, INC.	+12.08%	42.68B
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+47.07%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research